CoChat
Cited by 227

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

Open access
Huet, Sarah, Tesson, Bruno, Jais, Jean-Philippe, Feldman, Andrew L, Magnano, Laura, Thomas, Emilie, Traverse-Glehen, Alexandra, Albaud, Benoit, Carrère, Marjorie, Xerri, Luc, Ansell, Stephen M, Baseggio, Lucile, Reyes, Cécile, Tarte, Karin, Boyault, Sandrine, Haioun, Corinne, Link, Brian K, Feugier, Pierre, Lopez-Guillermo, Armando, Tilly, Hervé, Brice, Pauline, Hayette, Sandrine, Jardin, Fabrice, Offner, Fritz, Sujobert, Pierre, Gentien, David, Viari, Alain, Campo, Elias, Cerhan, James R, Salles, Gilles · 2018 · The Lancet Oncology

Abstract

Background Patients with follicular lymphoma (FL) have heterogeneous outcomes. Predictor models able to distinguish, at diagnosis, patients at high versus low risk of progression are still needed. Methods The primary objective of this study was to use gene-expression profiling data to build a signature predictive of outcome in patients treated in the rituximab era. In a retrospectively assembled training cohort of 134 pretreatment FL patients from the prospective randomized PRIMA trial, we developed an expression-based predictor of progression-free survival (PFS) that was further evaluated in FFPE samples obtained from three independent international cohorts, using NanoString technology. The validation cohorts comprised a distinct set of patients from the PRIMA trial (n=178), a cohort from the University of Iowa/Mayo Clinic Lymphoma SPORE (n=201) and the Hospital Clinic University of Barcelona (n=109). All tissue samples consisted of pretreatment diagnostic biopsies and were confirmed as FL grade 1-3a. The patients were all treated with regimens containing rituximab and chemotherapy, possibly followed by either rituximab maintenance or ibritumomab-tiuxetan consolidation. Findings The expression levels of 395 genes were associated with a risk of progression. Twenty-three genes reflecting both B-cell biology and tumor microenvironment were retained to build a predictive model, which identified a population at an increased risk of progression (p<0.0001). In a multivariate Cox model for PFS adjusted on rituximab maintenance treatment and FLIPI-1, this predictor was found to independently predict progression (adjusted hazard ratio (HR) of the high-risk compared to the low-risk group: 3.68; 95%CI: 2.19-6.17). The digital gene expression data met quality criteria for 460/488 (94%) FFPE samples of the validation cohorts. The predictor performances were confirmed in each of the individual validation cohorts (adjusted HR [95%CI] comparing high risk to low risk groups were respectively 2.57 [1.65-4.01], 2.12 [1.32-3.39] and 2.11 [1.01-4.41]). In the combined validation cohort, the median PFS values were 3.1 (95%CI: 2.4-2.8) and 10.8 (95%CI: 10.1-NR) years in the high- and low-risk groups, respectively. The risk of lymphoma progression at 2 years was twice as high in the high-risk group (38% (95%CI: 29-46) versus 19% (95%CI: 15-24)). In a multivariate analysis, the score predicted PFS independently of anti-CD20 maintenance treatment and of the FLIPI score (hazard ratio for the combined cohort, 2.30; 95%CI, 1.72-3.07). Interpretation We developed a robust 23-gene expression-based predictor of PFS, applicable to routinely available FFPE biopsies from FL patients at diagnosis. This score may allow individualizing therapy for patients with FL according to the patient risk category. Funding Roche Company, SIRIC Lyric, LYSARC, NIH and the Henry J. Predolin Foundation, Spanish Plan Nacional de Investigacion SAF2015-64885-R.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30102-5

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 227

Metadata

Authors
Huet, S., Tesson, B., Jais, J.-P., Feldman, A. L., Magnano, L., Thomas, E., Traverse-Glehen, A., Albaud, B., Carrère, M., Xerri, L., Ansell, S. M., Baseggio, L., Reyes, C., Tarte, K., Boyault, S., Haioun, C., Link, B. K., Feugier, P., Lopez-Guillermo, A., Tilly, H., Brice, P., Hayette, S., Jardin, F., Offner, F., Sujobert, P., Gentien, D., Viari, A., Campo, E., Cerhan, J. R., & Salles, G.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-04
Volume
19
Issue
4
Pages
549-561
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2789039113
Cited by
227
References
2
FWCI
18.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30102-5
The paper
Huet, S., Tesson, B., Jais, J.-P., Feldman, A. L., Magnano, L., Thomas, E., Traverse-Glehen, A., Albaud, B., Carrère, M., Xerri, L., Ansell, S. M., Baseggio, L., Reyes, C., Tarte, K., Boyault, S., Haioun, C., Link, B. K., Feugier, P., Lopez-Guillermo, A., . . . Salles, G. (2018). A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30102-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.